[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-568785-105":3,"detail-sidebar-cat-1-en-105":81,"doc-detail-568785-en":127},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mounjaro-summary-of-product-characteristics","Mounjaro - Summary of Product Characteristics","","Summary of Product Characteristics for Mounjaro, covering monitored medicinal use and guidance for healthcare professionals to report suspected adverse reactions. The document lists multiple presentations including pre-filled pen and vial options, with strengths from 2.5 mg to 15 mg and KwikPen multi-dose formats. It provides qualitative and quantitative composition details using oftirzepatide concentrations, describes the pharmaceutical form as a clear, colourless to slightly yellow injectable solution, and outlines clinical particulars including therapeutic indications for type 2 diabetes and weight management.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/mounjaro-summary-of-product-characteristics/568785/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mounjaro-summary-of-product-characteristics/568785.png","ImageObject",442,249,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-10-13",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What safety monitoring does the product require?","Question",{"text":63,"@type":64},"The product is subject to additional monitoring to enable quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which Mounjaro presentations and strengths are listed?",{"text":68,"@type":64},"The document lists pre-filled pen and vial solutions for injection, with strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. It also includes multi-dose KwikPen formats by dose strength.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the main therapeutic indications?",{"text":72,"@type":64},"Mounjaro is indicated for treatment of type 2 diabetes mellitus in adults, adolescents, and children aged 10 years and above when control is insufficient, as an adjunct to diet and exercise. It is also indicated for weight management in adults with elevated BMI, alongside a reduced-calorie diet and increased physical activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},568785,1792086975,{"code":4,"msg":82,"data":83},"success",[84,89,94,99,104,109,114,119,124],{"id":85,"doc_module":22,"doc_module_name":25,"category_name":86,"show_sort_weight":87,"slug":88},11,"Presentations",90,"presentations",{"id":90,"doc_module":22,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},12,"Resumes",80,"resumes",{"id":95,"doc_module":22,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},14,"Invoices",70,"invoices",{"id":100,"doc_module":22,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},15,"Posters",60,"posters",{"id":105,"doc_module":22,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},16,"Social Media",50,"social-media",{"id":110,"doc_module":22,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},17,"Forms",40,"forms",{"id":115,"doc_module":22,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},18,"Letters",30,"letters",{"id":120,"doc_module":22,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},21,"Paper Templates",5,"papers-templates",{"id":125,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":126},158,"general-158",{"code":4,"msg":82,"data":128},{"doc_id":79,"user_id":129,"nickname":42,"user_avatar":130,"doc_module":22,"category_id":125,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":136,"language":137,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":12,"update_tm":141,"read_time":142},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ANNEX I  \nSUMMARY OF PRODUCT CHARACTERISTICS  \nThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.  \n1. NAME OF THE MEDICINAL PRODUCT  \nMounjaro 2.5 mg solution for injection in pre-filled pen  \nMounjaro 5 mg solution for injection in pre-filled pen  \nMounjaro 7.5 mg solution for injection in pre-filled pen  \nMounjaro 10 mg solution for injection in pre-filled pen  \nMounjaro 12.5 mg solution for injection in pre-filled pen  \nMounjaro 15 mg solution for injection in pre-filled pen  \nMounjaro 2.5 mg solution for injection in vial  \nMounjaro 5 mg solution for injection in vial  \nMounjaro 7.5 mg solution for injection in vial  \nMounjaro 10 mg solution for injection in vial  \nMounjaro 12.5 mg solution for injection in vial  \nMounjaro 15 mg solution for injection in vial  \nMounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen  \nMounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen  \nMounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen  \nMounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen  \nMounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen  \nMounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen  \n2. QUALITATIVE AND QUANTITATIVE COMPOSITION  \nPre-filled pen, single-dose  \nMounjaro 2.5 mg solution for injection in pre-filled pen  \nEach pre-filled pen contains 2.5 mg oftirzepatide in 0.5 ml solution (5 mg/ml) .  \nMounjaro 5 mg solution for injection in pre-filled pen  \nEach pre-filled pen contains 5 mg oftirzepatide in 0.5 ml solution (10 mg/ml) .  \nMounjaro 7.5 mg solution for injection in pre-filled pen  \nEach pre-filled pen contains 7.5 mg oftirzepatide in 0.5 ml solution (15 mg/ml) .  \nMounjaro 10 mg solution for injection in pre-filled pen  \nEach pre-filled pen contains 10 mg oftirzepatide in 0.5 ml solution (20 mg/ml) .  \nMounjaro 12.5 mg solution for injection in pre-filled pen  \nEach pre-filled pen contains 12.5 mg oftirzepatide in 0.5 ml solution (25 mg/ml) .  \nMounjaro 15 mg solution for injection in pre-filled pen  \nEach pre-filled pen contains 15 mg oftirzepatide in 0.5 ml solution (30 mg/ml) .  \nVial, single-dose  \nMounjaro 2.5 mg solution for injection in vial  \nEach vial contains 2.5 mg oftirzepatide in 0.5 ml solution (5 mg/ml) .  \nMounjaro 5 mg solution for injection in vial  \nEach vial contains 5 mg oftirzepatide in 0.5 ml solution (10 mg/ml) .  \nMounjaro 7.5 mg solution for injection in vial  \nEach vial contains 7.5 mg oftirzepatide in 0.5 ml solution (15 mg/ml) .  \nMounjaro 10 mg solution for injection in vial  \nEach vial contains 10 mg oftirzepatide in 0.5 ml solution (20 mg/ml) .  \nMounjaro 12.5 mg solution for injection in vial  \nEach vial contains 12.5 mg oftirzepatide in 0.5 ml solution (25 mg/ml) .  \nMounjaro 15 mg solution for injection in vial  \nEach vial contains 15 mg oftirzepatide in 0.5 ml solution (30 mg/ml) .  \nPre-filled pen (KwikPen), multi-dose  \nMounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen  \nEach dose contains 2.5 mg oftirzepatide in 0.6 ml solution. Each multi-dose pre-filled pen contains 10 mg oftirzepatide in 2.4 ml (4.17 mg/ml). Each pen delivers 4 doses of 2.5 mg.  \nMounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen  \nEach dose contains 5 mg oftirzepatide in 0.6 ml solution. Each multi-dose pre-filled pen contains 20 mg oftirzepatide in 2.4 ml (8.33 mg/ml). Each pen delivers 4 doses of 5 mg.  \nMounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen  \nEach dose contains 7.5 mg oftirzepatide in 0.6 ml solution. Each multi-dose pre-filled pen contains 30 mg oftirzepatide in 2.4 ml (12.5 mg/ml). Each pen delivers 4 doses of 7.5 mg.  \nMounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen  \nEach dose contains 10 mg oftirzepatide in 0","cbCaieSvnz6nvHji","https://ap.wps.com/l/cbCaieSvnz6nvHji","pdf",3673021,202,"English","# Name of the medicinal product\n# Qualitative and quantitative composition\n# Pharmaceutical form\n# Clinical particulars\n## Therapeutic indications","[{\"question\":\"What safety monitoring does the product require?\",\"answer\":\"The product is subject to additional monitoring to enable quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.\"},{\"question\":\"Which Mounjaro presentations and strengths are listed?\",\"answer\":\"The document lists pre-filled pen and vial solutions for injection, with strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. It also includes multi-dose KwikPen formats by dose strength.\"},{\"question\":\"What are the main therapeutic indications?\",\"answer\":\"Mounjaro is indicated for treatment of type 2 diabetes mellitus in adults, adolescents, and children aged 10 years and above when control is insufficient, as an adjunct to diet and exercise. It is also indicated for weight management in adults with elevated BMI, alongside a reduced-calorie diet and increased physical activity.\"}]","Mounjaro - Summary of Product Characteristics | PDF",1791872371,71]